A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
- Conditions
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Interventions
- Registration Number
- NCT06551324
- Lead Sponsor
- Pfizer
- Brief Summary
Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment.
The primary objective of this clinical trial is to assess the radiographic progression free survival (rPFS) of the combination of PF-06821497 plus enzalutamide versus physician's choice of enzalutamide or docetaxel.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Male
- Target Recruitment
- 600
- Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features.
- Metastatic disease in bone documented on bone scan, or in soft tissue documented on CT/MRI scan.
- Progressive disease in the setting of surgical or medical castration with evidence of disease progression on treatment with abiraterone acetate in the mCSPC setting or first line mCRPC setting is required.
- Eastern Cooperate Oncology Group (ECOG) performance status 0 - 2, with life expectancy of at least 6 months as assessed by the investigator.
-
Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may make the participant inappropriate for the study.
-
Know history of active inflammatory gastrointestinal disease, chronic diarrhea, or previous gastric resection or lap-band surgery.
-
Clinically significant cardiovascular disease.
-
Known or suspected brain metastasis or active leptomeningeal disease or clinically significant history of seizure.
-
Prior treatment for prostate cancer at any stage with any cytotoxic chemotherapy, radioligand therapy (i.e. 177Lu-PSMA-617, radium 223), androgen receptor signaling inhibitors (ARSi) including enzalutamide, apalutamide, darolutamide, poly ADP-ribose polymerase (PARP) monotherapy or other systemic anti-cancer treatment, with the following exceptions:
- Treatment with first-generation antiandrogen agents, if discontinued prior to first dose of study intervention.
- Docetaxel treatment is allowed for mCSPC, as long as no signs of failure, or disease progression occurred during treatment or within 3 months of treatment completion.
-
Previous administration with an investigational product within 30 days or 5 half-lives preceding the first dose of study intervention (whichever is shorter).
-
Inadequate organ function.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm A PF-06821497 Investigational Arm A: PF-06821497 875 mg twice daily (BID) + enzalutamide 160 mg every day (QD) Arm A Enzalutamide Investigational Arm A: PF-06821497 875 mg twice daily (BID) + enzalutamide 160 mg every day (QD) Arm B Docetaxel Comparator Arm B: Physician's choice of enzalutamide 160 mg QD or docetaxel 75 mg/m2 intravenous (IV) every 21 days Arm B Enzalutamide Comparator Arm B: Physician's choice of enzalutamide 160 mg QD or docetaxel 75 mg/m2 intravenous (IV) every 21 days
- Primary Outcome Measures
Name Time Method Radiographic Progression Free Survival (rPFS) assessed by blinded independent central review (BICR) per RECIST v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) Randomization up to approximately 2 years. rPFS is defined as the time from the date of randomization to first objective evidence of radiographic progression as assessed in soft tissue per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or in bone per Prostate Cancer Clinical Trials Working Group 3 (PCWG3) guidelines by BICR, or death, whichever occurs first.
- Secondary Outcome Measures
Name Time Method Overall survival (OS) Randomization up to approximately 4.5 years. OS is defined as the time from the date of randomization to the date of death due to any cause.
Objective Response (ORR) Randomization up to approximately 2 years. The objective response rate is defined as the proportion of participants with measurable soft tissue disease at baseline who have a confirmed objective response of complete response (CR) or partial response (PR) per RECIST v1.1.
Time to first symptomatic skeletal event Randomization up to approximately 2 years. Time from randomization to first symptomatic skeletal event (symptomatic bone fractures, spinal cord compression, surgery or radiation to the bone whichever is first).
Change from baseline in patient reported pain symptoms per Brief Pain Inventory-Short Form (BPI-SF) Randomization up to approximately 4.5 years Analysis of Brief Pain Inventory-Short Form (BPI-SF) will be based on the pain severity score (mean of individual BPI-SF items 3, 4, 5 and 6), the pain interference score (mean of items 9A-9G), and the single BPI-SF Item 3 which asks the patient to rate pain at its worst in the last 24 hours.
Duration of Response (DoR) in measurable soft tissue disease Randomization up to approximately 2 years. The DoR is defined as the first objective evidence of soft tissue response (CR or PR, whichever is earlier) to radiographic progression or death due to any cause whichever occurs first.
Prostate Specific Antigen Response Randomization up to approximately 2 years. Proportion of participants with PSA response ≥50% in participants with detectable PSA values at baseline.
Change from baseline in health-related quality of life (HRQoL) per Functional Assessment of Cancer Therapy - Prostate (FACT-P) Randomization to approximately 4.5 years Change from baseline in HRQoL (FACT-P total score) will be presented. The FACT-P total score will be calculated based on the participant responses to the 39 items in the FACT-P questionnaire. Each item is rated on a 0 to 4 Likert-type scale and then combined to produce the FACT-P total score (0-156), with higher scores representing better health-related quality of life.
Time to prostate specific antigen (PSA) progression. Randomization up to approximately 2 years. Proportion of participants with PSA response ≥50% in participants with detectable PSA values at baseline.
Time to initiation of antineoplastic therapy. Randomization up to approximately 4.5 years. Time from randomization to first use of new antineoplastic therapy.
Incidence of Adverse Events Randomization up to approximately 4.5 years Type, incidence, severity \[as graded by National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) v5.0\], seriousness and relationship to study medications of AEs.
Change from baseline in emotional well-being per Functional Assessment of Cancer Therapy - Prostate (FACT-P) Randomization up to approximately 4.5 years Change from baseline in emotional well-being score will be presented. The emotional well-being score will be calculated based on 6 items in the FACT-P questionnaire; score range 0-24. Each item is rated on a 0 to 4 Likert-type scale
Change from baseline in social/family well-being per Functional Assessment of Cancer Therapy - Prostate (FACT-P) Randomization up to approximately 4.5 years Change from baseline in social/family well-being score will be presented. The social/family well-being score will be calculated based on 7 items in the FACT-P questionnaire; score range 0-28. Each item is rated on a 0 to 4 Likert-type scale
Change from baseline in functioning well-being per Functional Assessment of Cancer Therapy - Prostate (FACT-P) Randomization up to approximately 4.5 years Change from baseline in functioning well-being score will be presented. The functioning well-being score will be calculated based on 7 items in the FACT-P questionnaire; score range 0-28. Each item is rated on a 0 to 4 Likert-type scale
Change from baseline in physical well-being per Functional Assessment of Cancer Therapy - Prostate (FACT-P) Randomization to approximately 4.5 years Change from baseline in physical well-being score will be presented. The physical well-being score will be calculated based on 7 items in the FACT-P questionnaire; score range 0-28. Each item is rated on a 0 to 4 Likert-type scale
Change from baseline in symptoms per Functional Assessment of Cancer Therapy - Prostate (FACT-P) Randomization up to approximately 4.5 years Change from baseline prostate cancer symptoms (PCS) score will be presented. The PCS score will be calculated based on 12 items in the FACT-P questionnaire; score range 0-48. Each item is rated on a 0 to 4 Likert-type scale
Time to confirmatory deterioration in patient-reported pain symptoms per BPI-SF Item 3 "worst pain in 24 hours" Randomization up to approximately 4.5 years Defined as the time from randomization to onset of pain progression, which is defined as \> 2-point increase from baseline in the score from the BPI-SF Question 3 that is confirmed at the next consecutive assessment \> 4 weeks apart or an initial deterioration followed by death before the next assessment
Change from baseline in patient reported health status per European Quality of Life 5-Dimension 5 Level (EQ-5D-5L) Randomizaton up to approximately 4.5 years Participants will self-rate their current state of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression by choosing 1 of 5 possible responses that record the level of severity (no problems, slight problems, moderate problems, severe problems, or extreme problems) within each dimension. The questionnaire also includes a visual analog scale to self-rate general health state on a scale from "the worst health you can imagine" to "the best health you can imagine."
Time to definitive deterioration in patient-reported physical well-being per FACT-P Randomization up to approximately 4.5 years Time to definitive deterioration in physical well-being (PWB) per FACT-P is defined as the time from randomization to onset of definitive deterioration in physical well-being, which is defined as ≥3-point
Symptomatic toxicity as measured by items from the Patient-Reported Outcome CTCAE (PRO-CTCAE) Randomization up to approximately 4.5 years Each selected PRO-CTCAE items will be assessed related to one or more attributes that include counts for the frequency, severity, and/or interference with usual or daily activities.
Overall side effect burden as measured by the FACT- GP5 Randomization to approximately 4.5 years The FACT-GP5 question assesses overall side effect burden with the following response options "I am bothered by side effects of treatment," is rated on a 5-point scale ranging from "not at all" (0) to "very much" (4) and counts will be presented.
Time to definitive deterioration in patient-reported health related quality of life (HRQoL) per FACT-P Randomization up to approximately 4.5 years Defined as the time from randomization to onset of definitive deterioration in FACT-P total score, which is defined as \>10 point decrease from baseline and no subsequent observations with a \<10 point decrease from baseline FACT-P total score
To evaluate the PK of PF-06821497 when dosed with enzalutamide Cycle 1 (each cycle is 28 days), Day 1 to last PK draw at the end of Cycle 6, Day 1. PK characterized by pre-dose trough and post-dose plasma concentrations of PF-06821497 at selected visits.
To assess circulating tumor DNA (ctDNA) at baseline and on treatment to evaluate tumor burden. Baseline up to approximately 2 years. Evaluation of ctDNA burden at baseline and on study.
Trial Locations
- Locations (164)
Urology Centers of Alabama
🇺🇸Homewood, Alabama, United States
Arizona Urology Specialists- Provide ICF for Review Only
🇺🇸Tucson, Arizona, United States
Arizona Urology Specialists (AUS)-Orange Grove
🇺🇸Tucson, Arizona, United States
Sutter Santa Rosa
🇺🇸Santa Rosa, California, United States
Colorado Clinical Research
🇺🇸Lakewood, Colorado, United States
Florida Cancer Specialists
🇺🇸Venice, Florida, United States
Duly Health and Care
🇺🇸Westmont, Illinois, United States
Duly Health And Care
🇺🇸Lisle, Illinois, United States
NextStage Clinical Research-Chicago-(04)
🇺🇸Lisle, Illinois, United States
The University of Louisville, James Graham Brown Cancer Center
🇺🇸Louisville, Kentucky, United States
University of Louisville Hospital
🇺🇸Louisville, Kentucky, United States
UofL Health Medical Center Northeast
🇺🇸Louisville, Kentucky, United States
New England Cancer Specialists
🇺🇸Westbrook, Maine, United States
AtlantiCare
🇺🇸Egg Harbor Township, New Jersey, United States
James J. Peters VA Medical Center
🇺🇸Bronx, New York, United States
Circuit Clinical /Crystal Run Healthcare LLP
🇺🇸Middletown, New York, United States
Circuit Clinical
🇺🇸Middletown, New York, United States
Crystal Run Healthcare
🇺🇸Monroe, New York, United States
Salisbury VA Medical Center
🇺🇸Salisbury, North Carolina, United States
Keystone Urology Specialists
🇺🇸Lancaster, Pennsylvania, United States
AUC Urologists, LLC
🇺🇸Myrtle Beach, South Carolina, United States
Carolina Urologic Research Center, LLC
🇺🇸Myrtle Beach, South Carolina, United States
Grand Strand Medical Center
🇺🇸Myrtle Beach, South Carolina, United States
Parkway Surgery Center
🇺🇸Myrtle Beach, South Carolina, United States
SCRI Oncology Partners
🇺🇸Nashville, Tennessee, United States
USA Clinical Trials
🇺🇸San Antonio, Texas, United States
Huntsman Cancer Institute
🇺🇸Salt Lake City, Utah, United States
Harborview Medical Center
🇺🇸Seattle, Washington, United States
Fred Hutchinson Cancer Center
🇺🇸Seattle, Washington, United States
University of Washington Medical Center - Montlake
🇺🇸Seattle, Washington, United States
Centro de Urología (CDU)
🇦🇷Caba, Buenos Aires, Argentina
Hospital Sirio Libanes
🇦🇷Capital Federal, Buenos Aires, Argentina
Instituto Alexander Fleming
🇦🇷Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Imagenes Mdq
🇦🇷Mar del Plata, Buenos Aires, Argentina
Instituto de Investigaciones Clínicas Mar del Plata
🇦🇷Mar del Plata, Buenos Aires, Argentina
Centro Medico Privado CEMAIC
🇦🇷Capital, Córdoba, Argentina
IMAXE
🇦🇷Buenos Aires, Argentina
Asociación de Beneficencia Hospital Sirio Libanés
🇦🇷Buenos Aires, Argentina
Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC)
🇦🇷Buenos Aires, Argentina
Icon Cancer Centre Wesley
🇦🇺Auchenflower, Queensland, Australia
Monash Health
🇦🇺Clayton, Victoria, Australia
Peter MacCallum Cancer Centre
🇦🇺Melbourne, Victoria, Australia
Hospital São Lucas da PUCRS
🇧🇷Porto Alegre, RIO Grande DO SUL, Brazil
CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
🇧🇷Santo André, SÃO Paulo, Brazil
Hospital Alemao Oswaldo Cruz
🇧🇷Sao Paulo, SÃO Paulo, Brazil
Hospital de Base de São José do Rio Preto
🇧🇷São José do Rio Preto, SÃO Paulo, Brazil
Fundação Faculdade Regional de Medicina de São José do Rio Preto
🇧🇷São José do Rio Preto, SÃO Paulo, Brazil
Instituto do Cancer Arnaldo Vieira de Carvalho
🇧🇷São Paulo, Brazil
IBCC - Núcleo de Pesquisa e Ensino
🇧🇷São Paulo, Brazil
Sunnybrook Research Institute
🇨🇦Toronto, Ontario, Canada
Centre Hospitalier de l'Université de Montréal
🇨🇦Montréal, Quebec, Canada
Wannan Medical College Yijishan Hospital
🇨🇳Wuhu, Anhui, China
Beijing Friendship Hospital, Capital Medical University
🇨🇳Beijing, Beijing, China
Peking University Third Hospital
🇨🇳Beijing, Beijing, China
Chongqing University Cancer Hospital
🇨🇳Chongqing, Chongqing, China
Fujian Medical University Union Hospital
🇨🇳Fuzhou, Fujian, China
Fujian Cancer Hospital
🇨🇳Fuzhou, Fujian, China
Lanzhou university second hospital
🇨🇳Lanzhou, Gansu, China
Guangzhou First People's Hospital
🇨🇳Guangzhou, Guangdong, China
Southern Medical University Nanfang Hospital
🇨🇳Guangzhou, Guangdong, China
The Second Affiliated Hospital of Guilin Medical University
🇨🇳Guilin, Guangxi, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
🇨🇳Wuhan, Hubei, China
Hunan Cancer Hospital
🇨🇳Changsha, Hunan, China
Huai'an First People's Hospital
🇨🇳Huai'an, Jiangsu, China
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
🇨🇳Nanjing, Jiangsu, China
Nantong Tumor Hospital
🇨🇳Nantong, Jiangsu, China
The Second Affiliated Hospital of Soochow University
🇨🇳Suzhou, Jiangsu, China
The First Hospital of China Medical University
🇨🇳Shenyang, Liaoning, China
The First Affiliated Hospital of Xi'an Jiaotong University
🇨🇳Xi'an, Shaanxi, China
Shaanxi Provincial People' Hospital
🇨🇳Xi'an, Shaanxi, China
Yantai Yuhuangding Hospital
🇨🇳Yantai, Shandong, China
Tongji Hospital of Tongji University
🇨🇳Shanghai, Shanghai, China
West China Hospital, Sichuan University
🇨🇳Cheng Du, Sichuan, China
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
🇨🇳Hangzhou, Zhejiang, China
The First Hospital of Jiaxing
🇨🇳Jiaxing, Zhejiang, China
The first affiliated hospital of Ningbo university
🇨🇳Ningbo, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University
🇨🇳Wenzhou, Zhejiang, China
Fakultni nemocnice Olomouc
🇨🇿Olomouc, Olomoucký KRAJ, Czechia
Multiscan
🇨🇿Pardubice, Pardubický KRAJ, Czechia
Fakultni nemocnice Kralovske Vinohrady
🇨🇿PRague, Praha 10, Czechia
Fakultni Thomayerova nemocnice
🇨🇿Prague, Praha 4, Czechia
Nukleární Medicína
🇨🇿Hradec Králové, Czechia
Radiodiagnostika Pardubice
🇨🇿Pardubice, Czechia
Centre Antoine Lacassagne
🇫🇷Nice, Alpes-maritimes, France
Centre Antoine-Lacassagne
🇫🇷Nice, Alpes-maritimes, France
Institut de cancérologie Strasbourg Europe (ICANS)
🇫🇷Strasbourg, Alsace, France
CHRU de Brest
🇫🇷Brest, Finistère, France
Centre Hospitalier Universitaire de Nîmes - Institut de Cancérologie du Gard - Hôpital Universitaire
🇫🇷Nîmes, Gard, France
Oncopole Claudius Regaud
🇫🇷Toulouse, Haute-garonne, France
Hôpital Foch
🇫🇷Suresnes, Hauts-de-seine, France
Centre Hospitalier Privé Saint-Grégoire
🇫🇷Saint Grégoire, Ille-et-vilaine, France
Institut Jean Godinot
🇫🇷Reims, Marne, France
Centre Leon Berard
🇫🇷Lyon Cedex08, Rhône-alpes, France
Centre Hospitalier Lyon Sud
🇫🇷Pierre-Bénite, Rhône, France
Gustave Roussy
🇫🇷Villejuif, Val-de-marne, France
Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne
🇫🇷Clermont-Ferrand, France
Studienpraxis Urologie
🇩🇪Nürtingen, Baden-württemberg, Germany
Universitaetsklinikum Tuebingen
🇩🇪Tübingen, Baden-württemberg, Germany
Urologie Neandertal - Praxis Mettmann
🇩🇪Mettmann, Nordrhein-westfalen, Germany
Universitätsklinikum Münster - Albert Schweitzer Campus
🇩🇪Münster, Nordrhein-westfalen, Germany
Universitaetsklinikum Hamburg-Eppendorf
🇩🇪Hamburg, Germany
Alexandra General Hospital of Athens
🇬🇷Athens, Attikí, Greece
Athens Medical Center
🇬🇷Athens, Attikí, Greece
Metropolitan General Hospital
🇬🇷Athens, Attikí, Greece
Attikon General University Hospital
🇬🇷Chaidari, Attikí, Greece
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
🇮🇹Meldola, Emilia-romagna, Italy
Istituto Nazionale Tumori Regina Elena
🇮🇹Roma, Lazio, Italy
Ospedale San Raffaele
🇮🇹Milano, Italy
Chiba cancer center
🇯🇵Chiba-shi, Chiba, Japan
National Cancer Center Hospital East
🇯🇵Kashiwa, Chiba, Japan
National Hospital Organization Shikoku Cancer Center
🇯🇵Matsuyama, Ehime, Japan
National Hospital Organization Hokkaido Cancer Center
🇯🇵Sapporo, Hokkaido, Japan
Hokkaido University Hospital
🇯🇵Sapporo, Hokkaido, Japan
Kobe University Hospital
🇯🇵Kobe, Hyogo, Japan
Kanazawa University Hospital
🇯🇵Kanazawa, Ishikawa, Japan
Yokohama City University Medical Center
🇯🇵Yokohama, Kanagawa, Japan
Yokosuka Kyosai Hospital
🇯🇵Yokosuka, Kanagawa, Japan
The University of Osaka Hospital
🇯🇵Suita, Osaka, Japan
Keio university hospital
🇯🇵Shinjuku-ku, Tokyo, Japan
National Hospital Organization Kyushu Cancer Center
🇯🇵Fukuoka, Japan
National Hospital Organization Kumamoto Medical Center
🇯🇵Kumamoto, Japan
Osaka International Cancer Institute
🇯🇵Osaka, Japan
Yamagata University Hospital
🇯🇵Yamagata, Japan
Chonnam National University Hwasun Hospital
🇰🇷Hwasun, Jeonranamdo, Korea, Republic of
National Cancer Center
🇰🇷Goyang-si, Kyǒnggi-do, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of
Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of
Ewha Womans University Mokdong Hospital
🇰🇷Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of
Kyungpook National University Chilgok Hospital
🇰🇷Daegu, Taegu-kwangyǒkshi, Korea, Republic of
Frisius Medisch Centrum
🇳🇱Leeuwarden, Fryslân, Netherlands
Canisius-Wilhelmina Ziekenhuis
🇳🇱Nijmegen, Gelderland, Netherlands
Tergooiziekenhuizen, locatie Hilversum
🇳🇱Hilversum, Noord-holland, Netherlands
Meander Medisch Centrum
🇳🇱Amersfoort, Utrecht, Netherlands
MICS Centrum Medyczne Torun
🇵🇱Torun, Kujawsko-pomorskie, Poland
Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o.
🇵🇱Kraków, Małopolskie, Poland
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie
🇵🇱Kraków, Małopolskie, Poland
Univerzitna nemocnica Martin
🇸🇰Martin, Slovakia
MILAB, s.r.o., Urologicka ambulancia
🇸🇰Presov, Slovakia
BEKY - MED, s.r.o.
🇸🇰Presov, Slovakia
Fakultna nemocnica Trnava
🇸🇰Trnava, Slovakia
Cancercare Langenhoven Drive Oncology Centre
🇿🇦Port Elizabeth, Eastern CAPE, South Africa
Wilgers Oncology Centre
🇿🇦Pretoria, Gauteng, South Africa
TASK Eden
🇿🇦George, Western CAPE, South Africa
Hospital Clínic de Barcelona
🇪🇸Barcelona, Catalunya [cataluña], Spain
Hospital de la Santa Creu i Sant Pau
🇪🇸Barcelona, Catalunya [cataluña], Spain
Hospital Universitario Ramón y Cajal
🇪🇸Madrid, Madrid, Comunidad DE, Spain
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Madrid, Comunidad DE, Spain
Hospital Universitario HM Sanchinarro
🇪🇸Madrid, Spain
Althaia, Xarxa Assistencial Universitària de Manresa
🇪🇸Manresa, Spain
Hospital Universitari i Politecnic La Fe
🇪🇸València, Spain
Södersjukhuset
🇸🇪Stockholm, Stockholms LÄN [se-01], Sweden
Kaohsiung Medical University Chung-Ho Memorial Hospital
🇨🇳Kaohsiung, Taiwan
Taichung Veterans General Hospital
🇨🇳Taichung, Taiwan
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Taipei Veterans General Hospital
🇨🇳Taipei, Taiwan
Chang Gung Medical Foundation-Linkou Branch
🇨🇳Taoyuan, Taiwan
Koç Üniversitesi Hastanesi
🇹🇷İstanbul, İ̇stanbul, Turkey
Memorial Ankara Hastanesi
🇹🇷Ankara, Turkey
Royal Blackburn Hospital
🇬🇧Blackburn, Blackburn WITH Darwen, United Kingdom
Western General Hospital
🇬🇧Edinburgh, Midlothian, United Kingdom
The Beatson West of Scotland Cancer Centre
🇬🇧Glasgow, United Kingdom